Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large. [Read More]
Sponsored by Our Lab is Everywhere
Clinical evidence may help patients' changing needs.
See the story behind the moderate to severe RA study that reveals outcomes of one biologic monotherapy.USA-916-82440LEARN MORE
The ACR sent a letter to CVS Caremark detailing how recent updates to its prior authorization forms for many biologic drugs are increasing the paperwork burden for rheumatology practices and hurting patients’ timely access to treatment. [Read More]